Cytomegalovirus (CMV), a b-herpevirus, has a high prevalence in most human populations. Primary infection is usually asymptomatic in healthy individuals and results in lifelong persistence, whereas CMV re-
activation in individuals with compromised immunity results in severe disease. Cell-mediated immunity has a central role in the control of CMV infection, and CD8 + T cells appear to be a critical component, as indicated by the results of studies of transplant recipients [1] [2] [3] . CMV has also been shown to have a major impact on disease progression and survival in human immunodeficiency virus (HIV)-infected patients [4] before the development of highly active antiretroviral therapy (HAART). Most patients have substantial recovery of T cell populations after the initiation of HAART [5, 6] . However, the recovery of CMV-or tetanus-specific T helper function is reduced, compared with that in healthy subjects [7] [8] [9] , whereas CD8 + T cell responses to CMV are enhanced [8] .
For adaptive immunity, the recognition of infected cells requires T cell receptor (TCR) interaction with highly specific peptide ligands bound to major histocompatibility complex (MHC) class I molecules [10, 11] . Endogenously produced proteins are cleaved by the 20S proteasome to generate short peptides that are then loaded onto MHC class I molecules for presentation to CD8 + T cells [12] . After triggering, antigen-responsive CD8 + T cells can display several effector mechanisms to control infection, including the secretion of cytokines/chemokines and the lysis of infected cells [13] . Cytotoxicity requires cell-to-cell contact and the presence of cytolytic molecules, such as perforin, granzyme A and B in specific cytotoxic granules, or CD95L on the surface of the effector cell [14] . Cytokines such as interferon (IFN)-g and tumor necrosis factor-a have both antiviral [15, 16] and broad immunoregulatory effects [16] . In humans, CD8 + T lymphocytes have been shown to be heterogeneous in their capacity for cytokine secretion and the expression of cytolytic molecules [17] .
The avidity of TCR binding has been shown to be a major factor in the activation and regulation of CD4 + T cells [18, 19] . It was suggested in the results of a study that used EpsteinBarr virus (EBV)-specific cytotoxic T lymphocyte (CTL) clones of relatively high avidity that the intensity of the CD8 interaction might vary, to maintain constant avidity [20] . Of importance, high TCR avidity also has been associated with moreefficient protection against tumors by CD8 + T cells [21, 22] . However, the impact of TCR avidity on the antiviral function of human CD8 + T cells has not been extensively investigated. Ex vivo cytotoxicity by CD8 + T cells specific for HIV [23] , CMV [8, 24] , or EBV [25] during chronic infection have been described elsewhere [23, 24] . In the present study, we expanded our earlier studies and investigated the role of TCR avidity in the effector function of CMV-specific CD8 + T cells from HIVinfected patients receiving HAART. The data show a 10,000-fold higher TCR avidity in peripheral blood mononuclear cells (PBMCs) with ex vivo cytotoxicity and secretion of IFN-g in high versus low responders. Moreover, only lymphocytes with high-avidity TCR and direct ex vivo antiviral cytotoxicity were able to recognize virally infected targets. Possible explanations for the polarized function of high-and low-avidity TCR, such as the frequency of responding cells and level of cell activation, were evaluated and ruled out. The results are consistent with the notion that the ex vivo function of CD8 + T cells is linked to the avidity of TCR for their cognate epitope on antigenpresenting cells (APCs).
SUBJECTS, MATERIALS, AND METHODS

Subjects.
Twenty-five HIV-infected subjects receiving HAART were followed prospectively at the Rand-Schrader 5P21 AIDS Clinic, Los Angeles County and University of Southern California Medical Center (Los Angeles, CA). All patients received HAART for у2 years. HLA type was determined by polymerase chain reaction (PCR), as described elsewhere [26] for all patients in that study (HLA Typing Laboratory, the City of Hope). CMV serological status was determined by indirect immunofluorescence (Hemagen Diagnostic) at the Clinical Microbiology Laboratory (City of Hope). Written consent was obtained from patients, and the institutional review boards of the City of Hope and University of Southern California Medical School approved the study. The human experimentation guidelines of the US Public Health Service were followed at the respective institutions.
Virus load measurements. The HIV RNA copy number was determined by the Roche Amplicor HIV-1 Ultrasensitive test (Roche Molecular Systems), which has a lower limit of detection of 50 copies/mL. Cell-associated CMV was detected by a 2-stage nested PCR assay using a lysate of patient PBMCs, as described elsewhere [8] . The detection limit of this assay is 1 CMV DNA copy/ PBMC. 4 1.3 ϫ 10 Synthetic peptides. The HLA-A*0201 (A2) epitope (CMV pp65 495-503 NLVPMVATV) [27] , HLA-A*6801 (A68) epitope (CMV pp65 [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] FVFPTKDVALR), the HLA-B*0702 (B7) epitope (CMV pp65 265-275 RPHERNGFTVL) [28] , and the HLA-B*3502 (B35) epitope (CMV pp65 188-195 FPTKDVAL) were synthesized and purified as described elsewhere [27] . HLAmismatched motifs derived from the CMV genome sequence [28] were used as negative controls.
CTL assays. For ex vivo assays, cytotoxicity was measured in a 4-h 51 Cr-release assay using fresh PBMC isolated by FicollPaque (Amersham Pharmacia) separation as effector cells at the indicated effector:target (E:T) ratios. For ex vivo nonresponders, PBMCs stimulated with 100 mmol/L cognate peptide for 5 days were used as effectors for cytotoxicity. No in vitro costimulation or exogenous interleukin (IL)-2 was used in the assays. Target cells were autologous or mismatched EBV-transformed lymphoid cell lines (LCLs) used either infected with recombinant vaccinia viruses (VVs) or sensitized with peptide. For the preparation of infected targets, cells were infected overnight with recombinant VV expressing CMV pp65 (vpp65) or a wild-type control at an MOI of 5. For peptide sensitization, LCLs were incubated with 50 mmol/L specific or control peptides for 30 min or were left untreated, to serve as additional controls. Data are expressed as the percentage of specific lysis, defined as lysis)]/ 100 ϫ [(experimental lysis) Ϫ (spontaneous [total (detergent lysis)]. Maximum sponlysis) Ϫ (spontaneous taneous release values were always !20% of total release values.
Detection of secreted IFN-g by ELISA. Secreted IFN-g was measured in supernatants of PBMCs stimulated with CMV-derived peptides or LCLs infected with recombinant VV expressing CMV pp65 at an MOI of 5. Monoclonal antibody (MAb) NIB42 and biotinylated 4S.B3 were used as capture and detection reagents, respectively (PharMingen). Complexes were detected by incubation with streptavidin/peroxidase conjugate and reaction with o-phenylenediamine dihydrochloride (Sigma-Aldrich). Recombinant IFN-g (PeproTech) was used for the preparation of standard curves. Each sample was tested in duplicate.
Detection of IFN-g-secreting lymphocytes by ELISPOT. IFN-g-secreting lymphocytes were detected using antigen-spe-cific ELISPOT assay. In brief, 96-well plates supporting cellulose ester membranes (MultiScreen HA) were coated with 10 mg/ mL NIB42 MAb in sterile PBS by overnight incubation at 4ЊC. Empty binding sites were blocked by incubation with sterile PBS that contained 1% bovine serum albumin (BSA). PBMCs ( /well) were added to MAb-coated wells in the presence 5 2 ϫ 10 of 100 mmol/L HLA-matched CMV peptides. For each patient, PBMCs receiving medium only and HLA-mismatched CMV peptides were used as negative controls, and phytohemagglutinin (PHA) was used as the positive control. Bound IFN-g was detected by 3 h of incubation at 21ЊC with 0.5 mg/mL biotinylated anti-IFN-g MAb 4S.B3 (both from PharMingen), followed by consecutive incubation with streptavidin/peroxidase and H 2 O 2 /3-amino-9-ethyl carbazole as the substrate (all from Sigma). Each sample was tested in duplicate.
Tetramer synthesis and phenotypic labeling. Tetrameric peptide-MHC class I complexes were made as described elsewhere [8, 29] . In brief, recombinant b 2 -microglobulin and the extracellular portion of the MHC class I heavy chain were expressed in Escherichia coli. Inclusion bodies were extracted, washed, mixed with the CMV pp65 495-503 (A2 tetramers), pp65 [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] (A68 tetramers), or pp65 265-275 (B7 tetramers) peptides, and solubilized in 8 mol/L urea before refolding by dilution. The refolded complexes were purified by ion exchange followed by gel filtration chromatography, biotinylated with BirA, and assembled into tetramers with allophycocyanin (AP)-labeled streptavidin. Staining was done on cells with 1 mg tet- [188] [189] [190] [191] [192] [193] [194] [195] peptide (B35 tetramers, AP-labeled). Antibodies specific for CD28 (FITC-labeled), CD45RA, CD62L, and CD69 (CyChrome-labeled; Pharmingen) were used for the phenotypic characterization of cells. Biotinylated anti-CD122 was used for detection of membrane-expressed IL-2Rb, followed by staining with streptavidin-phycoerythrin (PE) conjugate. For the intracellular staining of perforin and granzyme A, cells were fixed and permeabilized using Cytofix/Cytoperm reagents, according to the manufacturer's instructions (BD Immunocytometry Systems). Antibodies to perforin (PE-labeled), granzyme A (FITClabeled), and the respective isotype controls were used for the intracellular staining of fixed cells. All antibodies were from BD Immunocytometry Systems. Preparations were analyzed in the dual-laser FACSCalibur (Becton Dickinson) using Cellquest software (BDIS). Fifty thousand events were scored for each sample, and the detection of surface markers and intracellular perforin or granzyme A was done in tetramer-positive (tet + ) CD8 + T cells by electronic gating. Detection of IFN-g by intracellular staining. PBMCs were stimulated for 6 h with peptides or with autologous infected LCLs used at a 100:1 ratio after being prepared as described above for the ex vivo CTL assays. No additional stimuli were used for the direct ex vivo detection of IFN-g. For both procedures, Brefeldin A (1 mmol/L; PharMingen) was added during the last 4 h of incubation. Cells were then stained with PElabeled anti-CD8 and CyChrome-labeled anti-CD45RA or anti-CD62L MAbs. After fixation and permeabilization, cells were incubated with AP-labeled anti-human IFN-g MAbs in wash/ permeabilization buffer, according to the manufacturer's instructions (all antibodies from PharMingen). Stained preparations were analyzed on a FACSCalibur flow cytometer (Becton Dickinson). Fifty thousand events were scored for each sample.
Characterization of TCR Vb subtype expression. PBMCs ( ) were incubated with 2.5 mg of AP-labeled A2 (P26) 6 5 ϫ 10 or B7 (P23) tetramers for 20 min at 4ЊC. Cells were washed and divided in aliquots for staining with FITC-or PE-labeled antibodies to 24 TCR Vb specificities, according to the manufacturer's instructions (IO Test; Betamark, Beckman-Coulter).
After the second staining, cells were washed and analyzed by flow cytometry. Statistical methods. Six patients were selected for detailed investigation: 3 with potent ex vivo cytotoxicity and 3 with undetectable ex vivo cytotoxicity against CMV peptides presented under specified HLA class I types. These 2 groups of subjects formed 2 strongly distinct clusters for several measurements of immune function. For any of these measurements, a nonparametric Wilcoxon test yielded a 1-sided significance level of .05. That test did not, however, reflect the strong clustering of the 2 groups, so we applied 2-sided Student's t tests for the comparisons of IFN-g, perforin, and granzyme A. We used analysis of variance for the ex vivo cytotoxicity grouping effect, to group by time interaction and to indicate the level of significance for the concentration curves in figure 1B.
RESULTS
Ex vivo cytotoxicity correlates with high peptide avidity.
Cytotoxicity against CMV can be detected in freshly isolated PBMCs from some, but not all, HIV-infected individuals [8, 23] . To investigate the mechanism for this dichotomy, we compared the avidity of CD8 + T cells for their cognate peptide in PBMCs with or without ex vivo cytotoxicity. Of a cohort of 25 HIV-infected subjects, 6 were selected for further study according to the availability of characterized CMV CTL epitopes (table 1) . P02, P20, and P23 had potent ex vivo cytotoxicity against CMV peptides presented under HLA-A*0201, -*6801, and -*B702, restriction, respectively (figure 1A). At an E:T ratio of 80:1, these patients had 36%, 47%, and 43% of specific lysis, respectively. The avidity of the effector cells for their cognate peptide was evaluated by the determination of secreted IFN-g by capture immunoassay in supernatants from PBMCs cultured for 24 h with a dilution series of the peptide of 100-0.01 mmol/ L (figure 1B). In cultures from lymphocytes with ex vivo cytotoxicity, IFN-g secretion was potent and detectable at as low as 10 nmol/L peptide, which indicated that the avidity of the responding lymphocytes for their cognate peptide was high. Conversely, P25, P26, and P29 lacked detectable ex vivo cytotoxicity (figure 1A), and IFN-g secretion was significantly lower ( , by repeated-measures analysis of variance), P p .002 compared with the group with ex vivo killing. In fact, the signal from lymphocytes without ex vivo cytotoxicity in response to increased ligand concentration (figure 1B) was not significantly different from a flat line ( ). The maximum amount of P 1 .06 secreted IFN-g in this group of patients was 640 pg/mL for P26, 250 pg/mL for P29, and 205 pg/mL for P25 when stimulated with 100 mmol/L A2 CMV peptide (P25 and P26) or the B35 CMV peptide (P29). These results demonstrate a clearcut difference in TCR avidity, because lymphocytes with high avidity had direct ex vivo cytotoxicity, without the need for further in vitro stimulation, whereas cells with low avidity did not. None of the 6 patients had detectable CMV DNA in peripheral blood (data not shown).
Substantial frequency of IFN-g-secreting cells in populations with high-or low-avidity TCR. The relationship between low avidity and minimal ex vivo cytotoxic responses in patient PBMCs shown in figure 1 might be explained by differences in frequencies of epitope-specific IFN-g-secreting lymphocytes. To address this question, the frequency of PBMCs secreting IFN-g in response to cognate CMV peptide, such as that shown in figure 1 , was investigated by ELISPOT (figure 2, white bars). A relatively high dose of peptide (100 mmol/L) was used, equivalent to the maximum amount used in figure 1 , to obtain the secretion of IFN-g even from lymphocytes with low avidity. PBMCs from patients with high-or low-avidity TCR were cultured for 16 h with medium only or with PHA or were stimulated with HLA-matched peptides. In the patient group with high-avidity responses to CMV epitopes, the frequencies were /10 6 PBMCs and spot-forming 1525 ‫ע‬ 390 950 ‫ע‬ 235 units (sfu)/10 6 PBMCs for patients P20 and P23, respectively. Similarly, in the patient group with low-avidity responses, the ELISPOT frequencies were sfu/10 6 PBMCs, 830 ‫ע‬ 5 1078 ‫ע‬ sfu/10 6 PBMCs, and sfu/10 6 PBMCs for patients 332 630 ‫ע‬ 15 P25, P26, and P29, respectively. There was a trend toward higher ELISPOT frequencies using CMV peptides among high-versus low-avidity responders, although the difference in frequencies did not reach statistical significance ( ). To further in-P p .5 vestigate the underlying mechanism causing differences in cytokine production between patient groups, PHA stimulation was used as a polyclonal activator resulting in ELISPOT responses independent of avidity to CMV-specific epitopes ( figure  2, gray bars) . ELISPOT frequencies were measured in parallel cultures of patient PBMCs, which resulted in frequencies of and IFN-g sfu/10 6 cells for P20 and P23, 3720 ‫ע‬ 220 975 ‫ע‬ 31 respectively. For P25, P26, and P29, the values were 1010 ‫ע‬ , , and IFN-g sfu/10 6 cells, respectively. 27 1313 ‫ע‬ 36 1240 ‫ע‬ 25 These results indicated that both PHA and the 100 mmol/L peptide dose gave ELISPOT frequencies that were nearly indistinguishable between the 2 patient groups. Together, these a Less than DL, below the detection limit of the assay (50 HIV RNA copies/mL).
results indicate that the frequency of cells with capacity for IFN-g secretion did not differ in patients groups with PBMCs of either high or low avidity. TCR avidity correlates with the capacity to recognize infected APCs. The T cell populations that were investigated presented extreme differences in avidity for their cognate peptide, which correlated with the capacity for ex vivo cytotoxicity. Therefore, to investigate whether differences in avidity also affected the recognition of naturally processed full-length CMVpp65 antigen, we studied the ability of these lymphocytes to recognize virally infected LCLs. PBMCs were cocultured with autologous LCLs infected with recombinant vpp65 at an E:T ratio of 10:1. LCLs infected with vpp65 at an MOI of 10 were doubly irradiated, to prevent vaccinia or LCL replication, as described in Subjects, Materials, and Methods. Culture supernatants recovered after 24 h were analyzed for IFN-g by capture immunoassay ( figure 3A) . Levels of IFN-g secreted by lymphocytes with high TCR avidity (P02, P20, and P23) were between 1.35 and 2.05 ng/mL. In contrast, IFN-g was below the detection limit of the assay in culture supernatants from lymphocytes with low TCR avidity-P25, P26, and P29 (P p .01 between responders and nonresponders, as determined by Student's t test). Parallel cultures containing cognate peptidepulsed LCLs were used in each case as internal positive controls (data not shown). No IFN-g was detected in control cultures that contained uninfected autologous LCLs or those infected with control recombinant virus. Figure 3B shows a representative experiment of intracellular staining for IFN-g with P02 PBMCs that confirms that CD8 + T cells were the responding population in these experiments. The remarkable contrast in IFN-g secretion between patient PBMCs with high and low avidity using recognition of natural processed CMV-pp65 as the readout provides an additional significant line of evidence confirming the results presented in figure 1.
Cytotoxic activity in ex vivo nonresponders can be detected after in vitro stimulation. We questioned whether CD8
+ T cells in PBMCs from patients without ex vivo cytotoxicity had an intrinsic defect in their cytolytic potential. This was investigated by combining the technique of in vitro stimulation followed by CTL assays of PBMCs with their cognate peptide. In cells without ex vivo cytotoxicity, peptide-specific lysis was detected after 5 days of stimulation (figure 4A). At an E:T ratio of 80:1, P25, P26, and P29 had 19%, 30%, and 43% specific lysis for the A2 peptide (P25 and P26) or the B35 peptide (P29), respectively. No lysis was detected against targets sensitized with A, Cytotoxicity detected after cells were stimulated with cognate peptide (A2 for P25 and P26 and B35 for P29) for 5 days. Cytotoxicity was determined against autologous targets sensitized with the cognate peptide (see figure 1A) . No cytotoxicity was detected against HLAmismatched cytomegalovirus-derived control peptides (data not shown). The data shown are representative of 2 independent determinations with similar results for each patient. B, Interferon (IFN) -g response to variable peptide concentration in cultures with detectable cytotoxicity (see figure  1B) . E:T, effector:target ratio.
HLA-mismatched CMV peptides. These results show that lymphocytes that were incapable of ex vivo cytolysis retain their cytolytic potential after a suitable period of stimulation, which suggests the lack of an intrinsic defect in cytotoxicity.
The response to peptide titration by PBMCs from patients who represent examples of low-avidity responses was evaluated after an initial 5-day stimulation with CMV-specific epitope (figure 4B). For P25 and P26, peak levels of IFN-g during restimulation were produced with 50 and 10 mmol/L specific peptide, respectively. The concentration of peptide needed to reach 50% of maximal IFN-g secretion was ∼20 and 2 mmol/ L peptide for PBMCs from P25 and P26, respectively. Thus, the dose required to get a half-maximal IFN-g response in this experiment was 20-200-fold higher than the dose required by fresh cells with high avidity (e.g., P02, P20, and P23) in ex vivo experiments (figure 1). These results highlight the association between the capability for cytotoxicity and the overall avidity of the TCR/peptide interaction.
Frequency of CMV-specific CD8 + T cells. The hypothesis that ex vivo cytolytic and IFN-g-secreting function may reflect the frequency of CMV-specific CD8 + T cells was evaluated by tetramer staining ( figure 5 ). In the 6 cases investigated, epitopespecific lymphocytes were detected at substantial frequencies, irrespective of ex vivo function. Thus, in the group of ex vivo responders, P02, P20, and P23 had 4.1%, 4.5%, and 7.9% of CD8 + T cells specific for the A2, A68, and B7 tetramers, respectively. In the group of ex vivo nonresponders, P25, P26, and P29 had 1.6%, 9.1%, and 3.3% of CD8 + T cells specific for the A2 (P25 and P26) and B35 tetramers (P29), respectively. The intensity of CD8 staining was similar in all tet + lymphocytes. Therefore, the frequency of epitope-specific CD8 + T cells was substantial in populations with low-avidity TCR, as shown by ELISPOT for IFN-g and tetramer staining. These results show that (1) epitope-specific lymphocytes were present at substantial frequencies in both ex vivo responders and nonresponders, (2) frequencies of tet + lymphocytes do not correlate with ex vivo functions, and (3) differences in ex vivo function in these patients are not linked to levels of CD8 expression. Cytolytic effector molecules and phenotype of tet + lymphocytes. Cytolysis by virus-specific CD8 + T cells requires perforin and granzyme A/B [30, 31] . Levels of the cytolytic effector molecules perforin and granzyme A were evaluated by intracellular staining (table 2) . On average, the extent of perforin detection was 3-fold higher in lymphocytes from ex vivo responders than in nonresponders ( and 7.5% ‫ע‬ 1.5% 2.5% ‫ע‬ , respectively; 2-sided ). Granzyme staining was 1.1% P p .01 and for lymphocytes with or 83.6% ‫ע‬ 5.9% 69.7% ‫ע‬ 3.8% without detectable ex vivo function, respectively (2-sided ). These results indicate a lower expression of cytolytic P p .03 effector molecules in cells with no ex vivo effector function.
To investigate potential phenotypic differences in tet + populations, the surface expression of the activation markers CD28, CD45RA, and CD69, as well as the memory marker CD62L, was investigated by flow cytometry. Plots with phenotyping from P23 and P26, representing CD8 + T cells from ex vivo responders and nonresponders, respectively, are shown in figure  6 . Double-positive (tet + /CD8 + ) events were collected by electronic gating. Quad settings for analysis of each marker were determined by staining with isotype control reagents and the staining of total PBMCs, so that distinct positive and negative populations could be identified. A majority of tet + lymphocytes were CD28 low (91.1% and 78.1% in P23 and P26, respectively), whereas about one-half of the population (61.7% and 44.2%) was CD45RA
+ . Only a small proportion of tet + lymphocytes (6.2% in P23 and 15.2% in P26) expressed the early activation antigen CD69, but a substantial percentage had low expression of CD62L (60.5% in P23 and 84.5% in P26), which indicates a memory phenotype. Both P23 and P26 tet + /CD8 + cells expressed CD122, the IL-2Rb subunit (99.1% and 100%, respectively). Furthermore, staining with a repertoire of antibodies covering a panel of 24 TCR Vb subtypes indicated that the tet + populations in both subjects represented oligoclonal expansions ( figure 7) . A vast majority of tet + lymphocytes in P23 expressed TCR Vb14, whereas, in P26, a majority of cells expressed Vb8 and Vb3, and minor frequencies were found in Vb20 and Vb21.3. The observed oligoclonal expansions were in agreement with the results of previous investigations that used CMV-specific CTL lines [32, 33] .
DISCUSSION
These data show that the ex vivo function of CMV-specific CD8 + T cells in HIV-infected patients receiving HAART is linked to the TCR avidity for the cognate epitope. Our study is the first to propose a mechanism for fresh ex vivo cytotoxicity against viral agents found in the peripheral blood of persistently infected individuals. The data also demonstrate that epitopespecific lymphocytes detected by tetramer staining, but without ex vivo function, have an intrinsic low avidity for the cognate epitope. The difference in TCR avidity between killer and nonkiller lymphocytes was 110,000-fold and correlated directly with the ex vivo capacity to recognize infected targets. Ex vivo cytotoxicity by CD8 + T cells has been observed against CMV and HIV in HIV-infected individuals [8, 23] and even in healthy carriers [24, 34] . The significance and potential protective role of virus-specific CD8 + T cells in such a functionally active status in persistently infected hosts is unclear, and the subclinical reactivation of CMV as a source of antigen cannot be excluded. It is noteworthy that high-avidity CTLs to tumor antigens have been shown to display a superior antitumor efficacy [21, 22, 35] . In the present study, the capacity of effector lymphocytes with high-avidity TCR to recognize and kill infected targets supports the hypothesis that such cells may have a protective role in vivo. This notion is further supported by murine models of viral infection that have shown that a high-avidity CTL response is associated with protective antiviral immunity [36, 37] . The results of studies on adoptive immunotherapy have also shown that the efficiency of the approach was linked to the avidity of effector cells for its cognate ligand [38] .
Virus-specific CD8 + T cells, detected by tetramer staining, but with limited or no function, have been described before against HIV [23, 39] and CMV [17, 24, 39] . Although the lymphocytes investigated here had significant frequencies of tet + populations, PBMCs from patients P23 and P26 represented extreme examples of the lack of correlation between tetramer reactivity and function. Of importance, the frequency of tet + populations as well as the functional profile of CMV-specific CD8 + T cells in each patient remained constant throughout the ∼2 years of the study. The reasons driving cell expansion to the levels detected by tetramers are currently unclear and deserve further investigation. The fact that CMV cannot be detected in peripheral blood even by a highly sensitive PCR in any of the subjects investigated suggests that protection against CMV in vivo is likely complex and involves other mechanism(s) in addition to CD8-mediated cytotoxicity (data not shown). In this context, the analysis of class II-mediated CD4 + T cell response by proliferation to CMV antigens showed no difference between lymphocytes with or without ex vivo function (data not shown).
Cytotoxicity mediated by perforin and granzyme constitutes an important effector function of CD8 + T cells. Variable levels of intracellular perforin have been described in HIV-and CMVspecific tet + lymphocytes [23, 24, 40] . Overall, our results are in agreement with those observations. However, our data also show a statistically significant higher frequency of perforinpositive lymphocytes in tet + populations of samples with ex vivo killing. T cell activation and differentiation are influenced by the potency of TCR signaling, as has been shown in mouse CD4 + T cells [18, 41] . Whether a similar relationship may exist for CD8 + T cells in currently unknown. Low perforin expression may be associated with low TCR avidity if a potent TCR/ligand interaction is required for the full development of effector function in CD8 + T cells. However, these observations could independently reflect the effect of other factors in the cellular environment, such as cytokines or chemokines, both of which are dysregulated in HIV infection.
CMV-specific tet + populations among ex vivo killer and nonkiller lymphocytes had similar profiles of activation and memory markers. In agreement with the results of previous studies and independent of effector function, most tet + lymphocytes were CD28 Ϫ [42] . Levels of CD45RA + cells were variable, ranging between 44% and 65% of tet + populations. Similarly, levels of CD62L were variable, and a majority of tet + cells had the CD62L low phenotype that characterizes memory lymphocytes.
Levels of the early activation marker CD69 were low, which argues against recent antigen exposure. In contrast, levels of the IL-2Rb (CD122) were uniformly high, which supports the observation that tet + cells, irrespective of ex vivo function, respond to IL-2 stimulation (data not shown).
The results of previous studies have indicated a link among reduced CD3-z expression in CD8 + T cells, an absence of cytotoxicity, and the degree of CD4 depletion in HIV infection [43] . The addition of IL-2 resulted in restored expression of the CD3-z chain and virus-specific cytotoxicity. However, in the populations studied in the present article, CD3-z expression in populations with high-or low-avidity TCR was similar (data not shown). Moreover, the cytotoxicity of ex vivo nonkiller cells was restored without exogenous IL-2 and required only TCR signaling though peptide stimulation ( figure 3 ). Although to a lesser extent than with peptide-sensitized targets, these effector lymphocytes could also recognize infected targets after in vitro stimulation with peptide (data not shown). Together, these observations indicate that CMV-specific CD8 + T cells from patients responding favorably to HAART are functional.
The results also indicate that cells from ex vivo nonkillers do not have an intrinsic defect in cytotoxic capacity. Instead, we argue that low-avidity interaction at the TCR/peptide level results in undetectable ex vivo effector function. Of significance, a peptide titration after 5 days of in vitro stimulation with specific peptide correlated with the detection of cytotoxicity, which provides further support for the interpretation that cytotoxicity requires a strong TCR/peptide interaction ( figure  4A ). The detection of cytotoxicity along with IFN-g secretion during a secondary stimulation in ex vivo nonresponders may be due to enhanced in vitro expression of adhesion molecules resulting in increased avidity of the overall interaction between the APC and the effector lymphocyte. An alternative explanation may be the expansion in vitro of a small population of CD8 + cells with greater avidity for the peptide. An interesting concept to explore is whether such populations can be induced to develop high TCR avidity by immunization with viral peptides, as has recently been shown for antitumor CD8 + T cells [44] .
